Hendrikus Jan Dubbink

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3429881/publications.pdf

Version: 2024-02-01

54 papers	2,968 citations	257101 24 h-index	197535 49 g-index
54 all docs	54 docs citations	54 times ranked	4361 citing authors

#	Article	IF	Citations
1	Combined molecular subtyping, grading, and segmentation of glioma using multi-task deep learning. Neuro-Oncology, 2023, 25, 279-289.	0.6	34
2	Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28, 2527-2535.	3.2	27
3	Fast detection of FOXF1 variants in patients with alveolar capillary dysplasia with misalignment of pulmonary veins using targeted sequencing. Pediatric Research, 2021, 89, 518-525.	1.1	4
4	The clonal relation of primary upper urinary tract urothelial carcinoma and paired urothelial carcinoma of the bladder. International Journal of Cancer, 2021, 148, 981-987.	2.3	12
5	Comparison of variant allele frequency and number of mutant molecules as units of measurement for circulating tumor DNA. Molecular Oncology, 2021, 15, 57-66.	2.1	28
6	â€œThe leading role of pathology in assessing the somatic molecular alterations of cancer: Position Paper of the European Society of Pathologyâ€• letter to the Editor. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 379-380.	1.4	1
7	Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica, 2021, 141, 945-957.	3.9	32
8	Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology, 2021, 23, 1547-1559.	0.6	34
9	Molecular Genetics of Conjunctival Melanoma and Prognostic Value of TERT Promoter Mutation Analysis. International Journal of Molecular Sciences, 2021, 22, 5784.	1.8	15
10	Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation. JCO Precision Oncology, 2021, 5, 849-853.	1.5	7
11	Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC) Tj ETQq1 1 0.784314 rgBT /Ov Oncology, The, 2021, 22, 813-823.	5.1	132
12	Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics. Journal of Molecular Diagnostics, 2021, 23, 816-833.	1.2	47
13	Response Letter. Journal of Thoracic Oncology, 2021, 16, e56.	0.5	0
14	The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma. Data in Brief, 2021, 37, 107191.	0.5	13
15	Gynecological Surveillance and Surgery Outcomes in Dutch Lynch Syndrome Carriers. Cancers, 2021, 13, 459.	1.7	2
16	Inâ€depth molecular analysis of combined and coâ€primary pulmonary large cell neuroendocrine carcinoma and adenocarcinoma. International Journal of Cancer, 2021, , .	2.3	6
17	Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. Neuro-Oncology, 2020, 22, 515-523.	0.6	140
18	Plasma Predictive Features in Treating EGFR-Mutated Non-Small Cell Lung Cancer. Cancers, 2020, 12, 3179.	1.7	11

#	Article	IF	Citations
19	Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation. Frontiers in Oncology, 2020, 10, 596.	1.3	13
20	TP53 Mutations in Serum Circulating Cell-Free Tumor DNA As Longitudinal Biomarker for High-Grade Serous Ovarian Cancer. Biomolecules, 2020, 10, 415.	1.8	23
21	Impact of panel design and cut-off on tumour mutational burden assessment in metastatic solid tumour samples. British Journal of Cancer, 2020, 122, 953-956.	2.9	21
22	MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?. Annals of Translational Medicine, 2020, 8, 1538.	0.7	0
23	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. Neuro-Oncology Advances, 2019, 1, vdz001.	0.4	9
24	Predicting the 1p/19q Codeletion Status of Presumed Low-Grade Glioma with an Externally Validated Machine Learning Algorithm. Clinical Cancer Research, 2019, 25, 7455-7462.	3.2	70
25	Response to: An immunohistochemical approach to detect oncogenic CTNNB1 mutations in primary neoplastic tissues. Laboratory Investigation, 2019, 99, 445-446.	1.7	0
26	Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 673-680.	1.4	24
27	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. Journal of Neuro-Oncology, 2018, 139, 349-357.	1.4	24
28	A novel tissueâ€based ÃŸâ€catenin gene and immunohistochemical analysis to exclude familial adenomatous polyposis among children with hepatoblastoma tumors. Pediatric Blood and Cancer, 2018, 65, e26991.	0.8	17
29	SNPitty. Journal of Molecular Diagnostics, 2018, 20, 166-176.	1.2	13
30	The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. Neuro-Oncology, 2018, 20, 1393-1399.	0.6	139
31	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. Neuro-Oncology, 2018, 20, 103-112.	0.6	220
32	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. Acta Neuropathologica Communications, 2018, 6, 126.	2.4	38
33	Multicenter Evaluation of the Idylla NRAS-BRAF Mutation Test in Metastatic Colorectal Cancer. Journal of Molecular Diagnostics, 2018, 20, 664-676.	1.2	19
34	Correlation of Gene Mutation Status with Copy Number Profile in Uveal Melanoma. Ophthalmology, 2017, 124, 573-575.	2.5	26
35	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathologica, 2017, 134, 957-959.	3.9	87
36	Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, The, 2017, 390, 1645-1653.	6.3	307

#	Article	IF	Citations
37	Metastatic Disease in Polyploid Uveal Melanoma Patients Is Associated WithBAP1Mutations. , 2016, 57, 2232.		16
38	Cell-free DNA mutations as biomarkers in breast cancer patients receiving tamoxifen. Oncotarget, 2016, 7, 43412-43418.	0.8	30
39	Cost-effectiveness of routine screening for Lynch syndrome in endometrial cancer patients up to 70 years of age. Gynecologic Oncology, 2016, 143, 453-459.	0.6	43
40	Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing. Journal of Molecular Diagnostics, 2016, 18, 775-786.	1.2	64
41	Cost-effectiveness of routine screening for Lynch syndrome in colorectal cancer patients up to 70 years of age. Genetics in Medicine, 2016, 18, 966-973.	1.1	42
42	Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 4128-4133.	3.3	28
43	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Neuro-Oncology, 2016, 18, 388-400.	0.6	143
44	TP53 mutated glioblastoma stem-like cell cultures are sensitive to dual mTORC1/2 inhibition while resistance in TP53 wild type cultures can be overcome by combined inhibition of mTORC1/2 and Bcl-2. Oncotarget, 2016, 7, 58435-58444.	0.8	8
45	Guidelines on Genetic Evaluation and Management of Lynch Syndrome. American Journal of Gastroenterology, 2015, 110, 192-193.	0.2	3
46	Mitochondrial D310 mutation as clonal marker for solid tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 467, 595-602.	1.4	12
47	Guidelines on genetic evaluation and management of Lynch syndrome. Gastrointestinal Endoscopy, 2015, 81, 243-244.	0.5	4
48	Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. Molecular Oncology, 2014, 8, 830-839.	2.1	44
49	Prevalence and Implications ofTERTPromoter Mutation in Uveal and Conjunctival Melanoma and in Benign and Premalignant Conjunctival Melanocytic Lesions. , 2014, 55, 6024.		74
50	Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology, The, 2014, 15, 943-953.	5.1	639
51	TERT promoter mutations and BRAF mutations are rare in sporadic, and TERT promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors. Journal of Neuro-Oncology, 2014, 120, 267-272.	1.4	17
52	A review on the molecular diagnostics of Lynch syndrome: a central role for the pathology laboratory. Journal of Cellular and Molecular Medicine, 2010, 14, 181-197.	1.6	62
53	Androgen Receptor Ligand-Binding Domain Interaction and Nuclear Receptor Specificity of FXXLF and LXXLL Motifs as Determined by L/F Swapping. Molecular Endocrinology, 2006, 20, 1742-1755.	3.7	42
54	Distinct Recognition Modes of FXXLF and LXXLL Motifs by the Androgen Receptor. Molecular Endocrinology, 2004, 18, 2132-2150.	3.7	102